Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

390 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Progression of JAK2-mutant polycythemia vera to CALR-mutant myelofibrosis severely impacts on disease phenotype and response to therapy.
Holmström MO, Novotny GW, Petersen J, Aaboe-Jørgensen M, Hasselbalch HC, Andersen MH, Nielsen SL, Fassi DE, Schöllkopf C. Holmström MO, et al. Among authors: andersen mh. Leuk Lymphoma. 2019 Dec;60(13):3296-3299. doi: 10.1080/10428194.2019.1633634. Epub 2019 Jul 1. Leuk Lymphoma. 2019. PMID: 31256699 No abstract available.
(GT)n Repeat Polymorphism in Heme Oxygenase-1 (HO-1) Correlates with Clinical Outcome after Myeloablative or Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation.
Køllgaard T, Kornblit B, Petersen J, Klausen TW, Mortensen BK, Brændstrup P, Sengeløv H, Høgdall E, Müller K, Vindeløv L, Andersen MH, Thor Straten P. Køllgaard T, et al. Among authors: andersen mh. PLoS One. 2016 Dec 20;11(12):e0168210. doi: 10.1371/journal.pone.0168210. eCollection 2016. PLoS One. 2016. PMID: 27997582 Free PMC article. Clinical Trial.
Sorted peripheral blood cells identify CALR mutations in B- and T-lymphocytes.
Kjaer L, Holmström MO, Cordua S, Andersen MH, Svane IM, Thomassen M, Kruse TA, Pallisgaard N, Skov V, Hasselbalch HC. Kjaer L, et al. Among authors: andersen mh. Leuk Lymphoma. 2018 Apr;59(4):973-977. doi: 10.1080/10428194.2017.1359743. Epub 2017 Aug 9. Leuk Lymphoma. 2018. PMID: 28792253 No abstract available.
The inhibitory checkpoint, PD-L2, is a target for effector T cells: Novel possibilities for immune therapy.
Ahmad SM, Martinenaite E, Holmström M, Jørgensen MA, Met Ö, Nastasi C, Klausen U, Donia M, Pedersen LM, Munksgaard L, Ødum N, Woetmann A, Svane IM, Andersen MH. Ahmad SM, et al. Among authors: andersen mh. Oncoimmunology. 2017 Nov 1;7(2):e1390641. doi: 10.1080/2162402X.2017.1390641. eCollection 2018. Oncoimmunology. 2017. PMID: 29308318 Free PMC article.
Spontaneous T-cell responses against the immune check point programmed-death-ligand 1 (PD-L1) in patients with chronic myeloproliferative neoplasms correlate with disease stage and clinical response.
Holmström MO, Riley CH, Skov V, Svane IM, Hasselbalch HC, Andersen MH. Holmström MO, et al. Among authors: andersen mh. Oncoimmunology. 2018 Feb 27;7(6):e1433521. doi: 10.1080/2162402X.2018.1433521. eCollection 2018. Oncoimmunology. 2018. PMID: 29872567 Free PMC article.
Cancer immune therapy for lymphoid malignancies: recent advances.
Klausen U, Jørgensen NGD, Grauslund JH, Holmström MO, Andersen MH. Klausen U, et al. Among authors: andersen mh. Semin Immunopathol. 2019 Jan;41(1):111-124. doi: 10.1007/s00281-018-0696-7. Epub 2018 Jul 13. Semin Immunopathol. 2019. PMID: 30006739 Review.
390 results